Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Truist Financial in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $743.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $709.00. Truist Financial‘s price […]

Truist Financial reiterated their hold rating on shares of FTI Consulting (NYSE:FCN – Free Report) in a report published on Monday,Benzinga reports. Truist Financial currently has a $180.00 price objective on the business services provider’s stock, up from their previous price objective of $158.00. Separately, Weiss Ratings raised FTI Consulting from a “sell (d+)” rating […]